Precision Biosciences (DTIL) Assets (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Assets of $143.9 million for Q1 2026, up 15.66% year-over-year from $124.4 million in Q1 2025, and down 6.82% quarter-over-quarter from $154.4 million in Q4 2025.
Precision Biosciences (DTIL) Assets (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Assets for 9 consecutive years, with $143.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 15.66% year-over-year to $143.9 million; the TTM figure through Mar 2026 stood at $143.9 million (up 15.66% YoY), while the FY2025 annual figure was $154.4 million, up 13.22% from the prior year.
- Assets declined to $143.9 million in Q1 2026 per DTIL's latest filing, from $154.4 million in the prior quarter.
- Across five years, Assets topped out at $297.2 million in Q2 2022 and bottomed at $93.5 million in Q3 2025.
- Historically, Assets has averaged $174.4 million across 5 years, with a median of $164.3 million in 2023.
- Annual changes were most pronounced in 2022 — Assets increased 29.14% — and 2023, when it sank 39.52%.
- Precision Biosciences' Assets stood at $238.2 million in 2022, then sank by 32.91% to $159.8 million in 2023, then decreased by 14.64% to $136.4 million in 2024, then increased by 13.22% to $154.4 million in 2025, then decreased by 6.82% to $143.9 million in 2026.
- Business Quant data shows DTIL's Assets at $143.9 million in Q1 2026, $154.4 million in Q4 2025, and $93.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 19.82 Bn |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 125.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.92 Mn |
| Mar 31, 2026 | 143.89 Mn |
| Dec 31, 2025 | 154.42 Mn |
| Sep 30, 2025 | 93.51 Mn |
| Jun 30, 2025 | 108.93 Mn |
| Mar 31, 2025 | 124.41 Mn |
| Dec 31, 2024 | 136.39 Mn |
| Sep 30, 2024 | 153.26 Mn |
| Jun 30, 2024 | 165.80 Mn |
| Mar 31, 2024 | 184.74 Mn |
| Dec 31, 2023 | 159.78 Mn |
| Sep 30, 2023 | 164.34 Mn |
| Jun 30, 2023 | 181.70 Mn |
| Mar 31, 2023 | 204.50 Mn |
| Dec 31, 2022 | 238.17 Mn |
| Sep 30, 2022 | 271.73 Mn |
| Jun 30, 2022 | 297.16 Mn |
| Mar 31, 2022 | 181.35 Mn |
| Dec 31, 2021 | 211.50 Mn |
| Sep 30, 2021 | 227.20 Mn |